Dai Fukumura

机构：Harvard University, Massachusetts General Hospital · ORCID：0000-0002-9505-4444

发表论文 596 篇 · 总被引 59199 次 · h-index 110

代表论文

• Targeting Tumor-derived Sphingosine Kinase 2 Unleashes Antitumor Immunity and Improves Survival of Mice with Group 3 Medulloblastoma (2026 · bioRxiv (Cold Spring Harbor Laboratory))
• Supplementary Table S2 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy (2026)
• Supplementary Fig. S10 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy (2026)
• Supplementary Fig. S2 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy (2026)
• Supplementary Fig. S7 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy (2026)
• Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy (2026)